- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07519018
TIS for Drug Resistant TLE (TITE-Effect)
Study on the Effect of Temporal Interference Stimulation in the Therapy of Drug Resistant Temporal Lobe Epilepsy
Temporal interference (TI) stimulation is a new neuromodulation method. Compared with traditional neuromodulation therapy, TI has deep targeting and focusing, and it has been confirmed to modulate sleep, cognition, and movement disorders. Recent study shown that TI stimulation targeting the hippocampus could significantly reduce epileptiform discharges, but its efficacy on seizures was still unclear. Therefore, the aim of this study is to observe the therapeutic effect of TI stimulation targeting the hippocampus in patients with refractory temporal lobe epilepsy (TLE) for 5 days, and to provide support for clinical trials of non-invasive treatment of refractory TLE.
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Xiaomu Wang
- Phone Number: 0086-029-84771055
- Email: wangxiaomu@fmmu.edu.cn
Study Locations
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710032
- Recruiting
- Xijing Hospital
-
Contact:
- Xiaomu Wang
- Phone Number: 0086-029-84771055
- Email: wangxiaomu@fmmu.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 to 65 years old;
- According to the 2010 International League Against Epilepsy (ILAE) diagnostic criteria for drug-resistant epilepsy;
- Temporal lobe epilepsy assessed by semiology, video electroencephalogram, and imaging;
- The duration of epilepsy was ≥2 years, and the average seizure frequency was ≥2 times per month in the 3 months before enrollment;
- Taking two or more antiepileptic drugs and continuing the same drug regimen for the duration of the trial;
- Could cooperate with the completion of treatment and related examinations;
- Patients and their family members fully understood and voluntarily signed the informed consent.
Exclusion Criteria:
- The anti-seizure medication therapy was adjusted during the treatment and follow-up period;
- Patient in status epilepticus;
- Patient with other systemic diseases leading to nervous system involvement and seizures;
- Patients with severe infection, cerebrovascular disease, malignant tumor and other diseases, accompanied by severe dysfunction of heart, liver, kidney and other organs, or accompanied by severe mental or cognitive impairment, or intractable hyperglycemia, or long-term use of corticosteroids;
- Patient with pregnant or lactating;
- Patients with contraindications to TI stimulation, fMRI examination or EEG examination, metal implants (pacemakers, metal dentures, metal IUD rings, etc.), or claustrophobia;
- Participating in other clinical trials;
- Patients or their family members withdrew informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Temporal interference
|
Temporal interference (TI) targeting hippocampus for 5 days. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Seizure Frequency Rate Change of One Month
Time Frame: One month after treatment
|
One month after treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Electroencephalogram Change
Time Frame: Baseline, 24 hours after treatment, one month after treatment, two months after treatment
|
Baseline, 24 hours after treatment, one month after treatment, two months after treatment
|
|
Rate of Seizure Frequency Rate Change of Two Month
Time Frame: Two month after treatment
|
Two month after treatment
|
Other Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
fMRI Change
Time Frame: Baseline, the moment after the first TI stimulation
|
Baseline, the moment after the first TI stimulation
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KY20262074
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.